Current Rheumatology Reports最新文献

{"title":"Frailty and Rheumatoid Arthritis: Key Insights and the Road Ahead.","authors":"Alexandra Legge, Grace Burns, Courtney Loecker, Devyani Misra, Katherine D Wysham","doi":"10.1007/s11926-026-01240-0","DOIUrl":"https://doi.org/10.1007/s11926-026-01240-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>People with rheumatoid arthritis (RA) experience premature aging and RA is associated with poor health outcomes. Frailty tools offer a holistic view of an individual's health status that may inform treatment strategies in RA. This review provides an overview of frailty in RA including methods of measurement, associations with clinical outcomes, and potential paths for frailty intervention.</p><p><strong>Recent findings: </strong>Frailty is common in RA, affecting approximately one-third of patients, with prevalence estimates varying according to the measurement instrument used. The causes of frailty are not well studied but likely include a combination of chronic systemic inflammation, immunosenescence, deconditioning and medication effects. Frailty is consistently associated with higher disease activity, poorer physical function, depression, pain, reduced quality of life, and greater comorbidity burden. Longitudinal studies show that frailty predicts hospitalization, serious infections, osteoporotic fractures, functional decline, readmission, and mortality, independent of traditional clinical risk factors and comorbidity indices. Emerging evidence also supports a bidirectional relationship between frailty and RA disease activity, suggesting that some aspects of frailty may be modifiable through improved disease control. Frailty-specific interventions have not yet been studied in RA, however, RA disease control, medication optimization and promotion of physical activity are likely to improve frailty in this high-risk population. Frailty is an important predictor of poor health outcomes in RA and may be amenable to interventions. Incorporation of frailty assessment into clinical care and clinical trials will be essential to move the field forward.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Information-seeking Behavior in Patients with Antiphospholipid Syndrome: A Scoping Review with Original Data.","authors":"Mickaël Noyé, Thomas Foret, Virginie Dufrost, Shirine Mohamed, Birgit Frotscher, Denis Wahl, Stéphane Zuily","doi":"10.1007/s11926-026-01236-w","DOIUrl":"10.1007/s11926-026-01236-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>Antiphospholipid syndrome (APS) is a complex disease that affects daily life. Previous studies have shown that poor information levels are correlated with lower health-related quality of life among individuals with APS. We conducted a scoping review on the available literature up to November 2025 to assess by what means health information-seeking behavior (HISB) among patients with APS has been evaluated. Furthermore, we conducted a cross-sectional survey in June 2021 to assess HISB among French-speaking patients with APS and to analyze HISB among internet posts related to APS between 2001 and 2021 using text analytics and cluster analysis.</p><p><strong>Recent findings: </strong>Five studies were retrieved and described according to the scoping review methodology. With respect to surveys among French patients with APS, the main source of information identified is rheumatologists/Lupus/APS specialists (more than 85% of patients). The internet and social media are used by up to 30% of patients. More than 80% of patients trust information provided by specialists, and they are most untrusting of online information. Approximately 75% of the patients were satisfied with their level of information. Using text provided by the survey and internet content, we identified three main profiles of HISB among APS patients: the most important subjects were pregnancy, treatments, daily life and burden associated with APS. New information tools are needed to provide trustworthy, first-hand information to address the main identified subjects of concern expressed by patients.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on 20 Years of Research on Tai Chi for Chronic Musculoskeletal Pain: An Updated Review.","authors":"Anthony Mark, Chenchen Wang","doi":"10.1007/s11926-026-01239-7","DOIUrl":"10.1007/s11926-026-01239-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>Chronic musculoskeletal pain (CMP), including osteoarthritis (OA), rheumatoid arthritis (RA), fibromyalgia, and chronic low back pain (cLBP), contributes substantially to disability and reduced quality of life. Contemporary pain science supports biopsychosocial, multimodal management addressing nociceptive, neuropathic, and nociplastic mechanisms. Tai Chi is a multicomponent mind-body exercise integrating gentle movement, breathing, relaxation, balance, and attentional focus. This narrative review summarizes approximately 20 years of research on Tai Chi for CMP and considers its evolving evidence in contemporary rheumatology and pain management.</p><p><strong>Recent findings: </strong>Findings are strongest for knee and hip OA, with randomized trials and systematic reviews demonstrating improvements in pain, mobility, physical function, and stiffness compared with non-exercise controls. For cLBP, studies suggest potential improvements in pain and physical function, although heterogeneity and limitations in the certainty of evidence warrant cautious interpretation. In fibromyalgia, Tai Chi may improve pain and selected symptoms, but findings remain variable and the certainty of evidence is limited. In RA, research is sparse and inconsistent, with insufficient data to establish clinically meaningful effects on disease activity, pain, or physical function. Across conditions, Tai Chi has a generally favorable safety profile, although variations in interventions and outcome measures limit direct comparisons. Over two decades, research on Tai Chi for chronic musculoskeletal pain has expanded from relatively small efficacy trials to larger randomized studies, as well as mechanistic and pragmatic investigations. Findings are most supportive for knee and hip OA, whereas evidence for cLBP and fibromyalgia remains promising but heterogeneous, with limitations in the certainty of evidence. Evidence for RA remains insufficient to draw firm conclusions. Overall, Tai Chi appears to be a feasible and generally safe nonpharmacological intervention that may complement multimodal management of musculoskeletal pain. Further high-quality studies are needed to establish the magnitude and clinical relevance of its benefits, determine comparative effectiveness and optimal dose and delivery, and evaluate longer-term outcomes.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seronegative Immune-Mediated Necrotizing Myopathy: An Overview for Optimal Clinical Management.","authors":"Dimitris C Kounatidis, Maria Dalamaga, Christina Zoubouli, Eleni Tsaroucha, Vasileios Stamatopoulos, Maria Konsta, Natalia G Vallianou","doi":"10.1007/s11926-026-01238-8","DOIUrl":"10.1007/s11926-026-01238-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Immune-mediated necrotizing myopathy (IMNM) is a rare and heterogeneous subgroup of idiopathic inflammatory myopathies. IMNM is broadly classified into seropositive disease, encompassing anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) and anti-signal recognition particle (anti-SRP) antibody-associated forms, and seronegative IMNM. Although seronegative IMNM has traditionally been considered largely analogous to seropositive disease, emerging evidence suggests that it may represent, at least in part, a distinct clinical entity. This review synthesizes the current evidence regarding the clinical management of seronegative IMNM.</p><p><strong>Recent findings: </strong>Seronegative IMNM typically presents with symmetric proximal muscle weakness, predominantly affecting the lower extremities. Recent data suggest that myalgia at disease onset may occur more frequently in seronegative patients, while evidence also indicates potential associations with prior statin exposure, malignancy, and connective tissue diseases; however, these relationships remain incompletely defined. Furthermore, extramuscular manifestations, particularly cardiac involvement, may be more clinically relevant than traditionally recognized. Muscle biopsy remains central to diagnosis, demonstrating prominent myofiber necrosis and regeneration with minimal inflammatory infiltrates, whereas research suggests that sarcolemmal membrane attack complex deposition may be less frequent than in seropositive IMNM. Immunosuppressive therapy constitutes the cornerstone of treatment, with glucocorticoids as first-line therapy and methotrexate commonly employed as the preferred steroid-sparing agent. Rituximab may be considered in refractory or relapsing disease. Seronegative IMNM is an uncommon and frequently underrecognized disorder. Significant gaps persist regarding its pathogenesis, associated comorbidities, and long-term outcomes. This narrative review provides a practical, evidence-based framework for the clinical evaluation and management of patients with seronegative IMNM.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutics in Axial Spondyloarthritis: A Review of What Works - SPARTAN 2026 Annual Meeting Proceedings.","authors":"Rafael Bassara Macedo, Carla Saad","doi":"10.1007/s11926-026-01234-y","DOIUrl":"10.1007/s11926-026-01234-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Axial spondyloarthritis (axSpA) encompasses a broad disease spectrum, and the management landscape has expanded considerably over the past two decades. This review synthesizes the current evidence on pharmacological and non-pharmacological interventions in axSpA, addressing both symptom control and radiographic outcomes across drug classes and patient contexts.</p><p><strong>Recent findings: </strong>NSAIDs remain the cornerstone of first-line therapy, with emerging long-term cohort data suggesting a dose-response relationship between NSAID exposure and reduced radiographic spinal progression in radiographic disease. TNF inhibitors retain the most mature evidence base regarding radiographic progression, with longitudinal data associating TNFi exposure with slower mSASSS progression and suggesting that this effect may be partially uncoupled from inflammation as measured by ASDAS, particularly with earlier treatment initiation. IL-17 inhibitors demonstrate robust symptomatic efficacy, while two-year structural data show low radiographic progression, although a treatment-specific structural effect has not been established. JAK inhibitors provide effective symptom control, and longer-term radiographic data are now available, but controlled evidence demonstrating inhibition of structural progression remains lacking. Exercise therapy, supported by a recent systematic review and meta-analysis, improves disease activity, function, mobility, pain, and fatigue, with subgroup analyses showing significant BASFI improvement only for sessions lasting ≤60 minutes. Obesity is associated with greater disease activity and poorer response to TNF inhibitors. Symptom control is achievable across all major drug classes in axSpA. Evidence regarding radiographic progression is most mature for TNF inhibitors, more limited for IL-17 inhibitors, context-dependent for NSAIDs, and currently insufficient to establish structural modification with JAK inhibitors. Effective management requires integrating pharmacological and non-pharmacological strategies, including structured exercise as an evidence-based intervention, while recognizing obesity as a clinically relevant prognostic factor.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why Do Some Therapies Work While Others Fail? Mechanisms of Response and Emerging Treatments in axial Spondyloarthritis: 2026 SPARTAN Annual Meeting Proceedings.","authors":"Brooke J Rutledge, Lisa Wang, Mizuki Nakamura, Akihiro Nakamura","doi":"10.1007/s11926-026-01235-x","DOIUrl":"10.1007/s11926-026-01235-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review summarizes recent advances in the pathogenesis of axial spondyloarthritis (axSpA), examines why TNF, IL-17, and JAK inhibition is effective whereas IL-23 blockade has not demonstrated clinical efficacy, and highlights emerging therapeutic targets.</p><p><strong>Recent findings: </strong>TNF, IL-17 A, and IL-17 F are key drivers of inflammation in axSpA and may also contribute to pathological new bone formation. HLA-B27 can present peptides to CD8⁺ T cells, potentially expanding pathogenic T-cell populations, including TRBV9⁺ (V9 T cell receptor beta chain) cells, that produce TNF and IL-17. Although antigen-presenting cell (APC)-derived IL-23 can promote IL-17 production, its contribution may be limited once inflammation is established, potentially explaining the lack of efficacy of IL-23 blockade in axSpA. In addition, a type I interferon (IFN) signature has been associated with anti-TNF/IL-17-refractory disease. Emerging therapeutic targets include TRBV9, macrophage migration inhibitory factor (MIF), and hypoxia-inducible factor-1α (HIF-1α). Current evidence validates TNF, IL-17, and JAK inhibition over IL-23 blockade. Type I IFN, TRBV9, MIF, and HIF-1α represent novel targets for future therapies.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the Clinical Spectrum of DNASE1L3 Deficiency: Insights from Case Series and Systematic Literature Review.","authors":"Hülya Ercan Emreol, Dilara Unal, Erdal Sag, Ozge Başaran, Yelda Bilginer, Seza Ozen","doi":"10.1007/s11926-026-01233-z","DOIUrl":"10.1007/s11926-026-01233-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;DNASE1L3 deficiency is a rare monogenic cause of lupus and lupus-like autoimmunity resulting from impaired extracellular DNA clearance and sustained immune activation. Although most reported patients present with early-onset systemic lupus erythematosus (SLE), emerging evidence suggests broader phenotypic variability, including vasculitic and overlap manifestations. Whether these presentations represent distinct clinical entities or a continuum of DNASE1L3-associated immune dysregulation remains unclear. We aimed to define the clinical spectrum of DNASE1L3 deficiency and examine the relationship between recurrent pathogenic variants and disease severity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a combined pediatric case series and systematic literature review. Four children with genetically confirmed biallelic DNASE1L3 variants followed at a tertiary pediatric rheumatology centre were retrospectively analysed for clinical, immunological, genetic, treatment, and outcome data. In parallel, a systematic search of PubMed/MEDLINE, Scopus, and Web of Science identified previously reported patients with confirmed biallelic pathogenic or likely pathogenic DNASE1L3 variants and extractable patient-level clinical data. To facilitate cross-case comparison, we applied an exploratory three-tier descriptive framework reflecting increasing disease severity: vasculitic or organ-limited disease (G1), systemic lupus or overlap phenotypes without irreversible organ damage (G2), and severe systemic organ-damaging disease (G3). The assigned grades were descriptive rather than permanent categories, as some patients may meet the criteria for a higher grade if broader systemic manifestations or irreversible organ damage develop during follow-up.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Fifteen reports provided extractable patient-level data, corresponding to 45 unique previously reported patients after accounting for known or probable overlapping reports. Combined with four patients from our centre, the analysis included 49 genetically confirmed individuals. SLE-dominant disease was the most frequent phenotype (27 [60%] of 45), followed by hypocomplementaemic urticarial vasculitis/HUVS-dominant disease (10 [22.2%]) and overlap phenotypes (8 [17.8%]). Renal involvement was reported in 30 (66.7%) of 45 patients, and disease onset occurred by age 3 years in 20 (44.4%). Persistent hypocomplementemia affecting C3 and C4 was frequently reported across the spectrum. Recurrent DNASE1L3 variants were observed across multiple phenotypic and severity grades. Variants such as p.Asn191Ser and p.Thr97Ilefs*2 occurred in patients spanning organ-limited vasculitic disease, lupus overlap phenotypes, and severe multisystem lupus with major organ involvement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;DNASE1L3 deficiency was associated with a broad clinical spectrum of immune-mediated disease rather than a single clinicopathological entity. The occurrence of identical ","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoinflammatory Syndromes of Hidradenitis Suppurativa: Updates in Clinical Features, Emerging Associations, and Management.","authors":"Jade Y Ho, Andrew L Liang, Carlo Alberto Maronese, Angelo Valerio Marzano, John M Davis, Vincent Piguet, Afsaneh Alavi","doi":"10.1007/s11926-026-01232-0","DOIUrl":"10.1007/s11926-026-01232-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>To summarize and critically evaluate recent literature on autoinflammatory syndromes of hidradenitis suppurativa (HS).</p><p><strong>Recent findings: </strong>HS-associated autoinflammatory syndromes traditionally encompass pyoderma gangrenosum (PG), acne, and HS (PASH); pyogenic arthritis, PG, acne, and HS (PAPASH); psoriatic arthritis, PG acne, and HS (PsAPASH); and PG, acne, HS and ankylosing spondylitis (PASS). However, this spectrum continues to expand, with recent literature considering the inclusion of additional autoinflammatory diseases such as HS associated with SAPHO, including synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO); and Hyperimmunoglobulin D Syndrome (HIDS). HS-associated autoinflammatory syndromes are thought to be driven by dysregulation of the innate immune system and the subsequent overexpression of key inflammatory cytokines such as IL-1, and targeted IL-1 therapies have demonstrated particularly brisk and efficacious response. Multiple genes related to follicular keratinization or inflammatory regulation have been implicated, and sequencing methods such as whole-exome sequencing and variant enrichment analysis continue to identify novel genetic variants and are being used to further elucidate genotype-phenotype correlations. HS-associated autoinflammatory syndromes are an evolving spectrum of rare, severe, diseases in which HS coexists with other autoinflammatory conditions, most commonly PASH and related syndromes. They are driven by innate immune dysregulation and pathogenic genetic variants, with whole-exome sequencing aiding diagnosis and genotype-phenotype correlation. Management is often challenging and highly individualized, with targeted biologic therapies such as IL-1 inhibitors showing the most consistent and rapid clinical benefit.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Health in Rheumatoid Arthritis: An Update.","authors":"Faidra Laskou, Elaine Dennison","doi":"10.1007/s11926-026-01230-2","DOIUrl":"10.1007/s11926-026-01230-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>Rheumatoid arthritis (RA) affects approximately 1% of the global population and is the most common inflammatory arthritis in adults. RA is well established as a significant risk factor for secondary osteoporosis (OP). Bone loss in RA occurs at three anatomically distinct levels: periarticular osteopenia, marginal erosions at the joint periphery, and generalised systemic OP. Understanding the complex mechanism underlying osteoclast-mediated bone loss in RA is essential for the development of targeted interventions, while identification of individuals at risk of OP and fracture remains paramount. This review will highlight recent advances in these areas.</p><p><strong>Recent findings: </strong>The cornerstone of bone loss management and prevention in RA remains disease activity control and reduction of inflammation. In this review, we will discuss the most recent advances in understanding the mechanism of bone loss in RA, the skeletal effects of current RA and anti-OP therapies in the RA population. We also highlight areas where future research may be focused to inform best management of bone health in these patients. RA associated bone loss remains a substantial contributor to morbidity, highlighting the need for improved fracture risk stratification, optimisation of therapeutic approaches, and greater standardisation of monitoring strategies. Critical evidence gaps persist, including the absence of validated RA specific fracture risk thresholds to guide treatment decisions and the lack of prospective randomised trials comparing bone protective agents in RA associated osteoporosis. Data in men with RA remain limited, and further work is required to delineate the relative skeletal effects of biologic therapies. Additionally, optimal DXA monitoring intervals for patients with stable disease on DMARD therapy are not well defined, contributing to considerable variation in clinical practice. Addressing these unmet needs will be essential to advancing bone health management and reducing fracture burden in individuals with RA.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13461950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual Dysfunction in Women with Axial Spondyloarthritis: A Narrative Review Integrating Quantitative Evidence.","authors":"Gabriela Stutz F Moreira, Hemerli de Cinque Almeida Esteves, Lucas M Barbosa, Lucas A S Alencar, Lara Guedes, Maryah C Stutz Martins, Victoria Navarro-Compán","doi":"10.1007/s11926-026-01231-1","DOIUrl":"10.1007/s11926-026-01231-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>Sexual dysfunction is an underrecognized but clinically relevant manifestation in women with axial spondyloarthritis (axSpA), with significant implications for quality of life. This review aims to provide a comprehensive synthesis of the biological, clinical, and psychosocial mechanisms underlying sexual dysfunction in axSpA, integrating available literature with supportive quantitative evidence.</p><p><strong>Recent findings: </strong>Emerging evidence demonstrates that sexual dysfunction in axSpA is common and multifactorial. Chronic inflammation may contribute to endothelial dysfunction, neuroendocrine alterations, and fatigue, which may indirectly affect physiological components of sexual response. Clinical factors such as pain, functional limitation, and reduced mobility further compromise sexual activity, while psychological burden; including depression, anxiety, and body image disturbance; plays a critical mediating role. Structural changes, including genital atrophy associated with disease duration, may also contribute to persistent dysfunction. Quantitative data from a meta-analysis involving 547 women suggest that there may be lower Female Sexual Function Index scores in patients with axSpA compared to healthy controls, despite the low-to-moderate certainty of evidence. This seems particularly evident in areas such as arousal, lubrication, orgasm, pain, and desire. Sexual dysfunction in women with axSpA appears to involve a complex interplay between inflammatory, physical, psychological, and structural factors. A multidisciplinary approach might be beneficial for improving patient outcomes, and systematic assessment of sexual health should be considered into routine care.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"28 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}